Perspectives
From 67% to 97%: That’s a big improvement
Point-of-sale edit upped % of Rx with <7 days supply
February 9, 2020A point-of-sale edit helped decrease large opioid supplies for new users, with a 30 percent increase in prescriptions of less than seven days supply
Evidence shows that a three-day opioid prescription is enough most of the time. The Centers for Disease Control (2016) provided these guidelines, and many states have passed laws that support them. These guidelines have worked their way into doctors’ prescribing habits, but for many, it’s a slow process. This study demonstrates how benefit design can have an immediate impact on prescribing behavior. This Blue Plan implemented a point-of-sale edit to limit new opioid prescriptions to less than seven days supply. This plan’s compliance rate jumped from 67 percent to 97 percent.
Related news
Perspectives
June 1, 2023
Prime reimagines patient care, unites care team for a better experience and smarter treatment plan
The patient journey from a cancer diagnosis through treatment with multiple specialty medications…
Perspectives
May 30, 2023
Specialty Drug Pipeline Update: May 2023
This monthly pipeline wrap-up provides a review of newly approved specialty drugs, recent…
Perspectives
May 30, 2023
Traditional Drug Pipeline Update: May 2023
This monthly pipeline wrap-up provides a review of newly approved traditional drugs, recent…